Benzinga | Nov 2, 2021 05:46PM EDT

Ultragenyx Pharmaceutical Q3 EPS $(1.08) Beats $(1.41) Estimate, Sales $81.65M Beat $81.55M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.41) by 23.4 percent. This is a 4.42 percent increase over losses of $(1.13) per share from the same period last year. The company reported quarterly sales of $81.65 million which beat the analyst consensus estimate of $81.55 million by 0.12 percent. This is a 0.22 percent increase over sales of $81.47 million the same period last year.